Our Story

Good Health Can’t Wait

Dr. Reddy’s in the United Kingdom

As a multinational pharmaceutical company, we are guided by our purpose to accelerate access to affordable and innovative medicines, because we believe that “Good Health Can’t Wait”. This credo unites over 24000 employees worldwide. We aspire to provide a culture of empathy and dynamism that allows us to understand the needs of our patients and partners. Today millions of patients in over 66 countries have access to Dr. Reddy’s products.

Our goal is always to ensure Good Health. For us, drugs are not just molecules, but tools that help patients heal. Can’t wait reflects our commitment to act quickly to find innovative solutions that address patients’ unmet needs and accelerate access to much-needed medicines for people around the world.

Since our establishment in 2002, we have supported UK’s healthcare system with our affordable prescription and OTC medicines portfolio. Our presence in the UK includes commercial offices in Cambridge, an R&D center in Cambridge, and an Active Pharmaceutical Ingredient (API) manufacturing site in Mirfield.

We work closely with the country’s healthcare partners to ensure that our medicines are available where needed. Our commitment to providing good health includes patients and the planet. As a PSCI (Pharmaceutical Supply Chain Initiative) member, we actively support the core principles of human rights, ethics, human rights and labor, health and safety, environment, and management systems. Since 2006, we are listed as one of the most sustainable pharmaceutical companies by the Dow Jones Sustainability Indices (DJSI).

Dr. Reddy’s in the United Kingdom

As a multinational pharmaceutical company, we are guided by our purpose to accelerate access to affordable and innovative medicines, because we believe that “Good Health Can’t Wait”. This credo unites over 24000 employees worldwide. We aspire to provide a culture of empathy and dynamism that allows us to understand the needs of our patients and partners. Today millions of patients in over 66 countries have access to Dr. Reddy’s products.

Our goal is always to ensure Good Health. For us, drugs are not just molecules, but tools that help patients heal. Can’t wait reflects our commitment to act quickly to find innovative solutions that address patients’ unmet needs and accelerate access to much-needed medicines for people around the world.

Since our establishment in 2002, we have supported UK’s healthcare system with our affordable prescription and OTC medicines portfolio. Our presence in the UK includes commercial offices in Cambridge, an R&D center in Cambridge, and an Active Pharmaceutical Ingredient (API) manufacturing site in Mirfield.

We work closely with the country’s healthcare partners to ensure that our medicines are available where needed. Our commitment to providing good health includes patients and the planet. As a PSCI (Pharmaceutical Supply Chain Initiative) member, we actively support the core principles of human rights, ethics, human rights and labor, health and safety, environment, and management systems. Since 2006, we are listed as one of the most sustainable pharmaceutical companies by the Dow Jones Sustainability Indices (DJSI).

Our promises

What we do to be true to our belief and achieve our purpose is driven by our five promises:

Brining expensive medicine within reach

Addressing unmet patient needs

Helping patients manage disease better

Enabling and helping our partners ensure that our medicines are available where needed

Working with partners to help them succeed

Our values

In keeping with our purpose of "Good Health Can't Wait", we try to create an environment of innovation and learning, in pursuit of excellence.

    We will uphold the highest standards of integrity and transparency in all our transactions

    Intégrité

    We are committed to providing safe work environments through continuous improvement of our infrastructure, work practices and behaviors.

    We are dedicated to designing quality into our products and processes to delight our stakeholders.

    Qualità

    We strive to achieve more with less, through a culture of innovation, continuous improvement, and a substantial focus on the elimination of waste.

    We are committed to creating a work environment that encourages diverse perspectives and upholds the dignity of work and individuals.

    We will leverage expertise and resources from across our global network to create greater value for our stakeholders.

    We will create value for our stakeholders in a manner that respects our natural environment and serves the best interests of the communities in which we live and work.

    Transparency

    Publication of data relating to business-to-health professionals:

    Dr. Reddy’s has always believed in the importance of transparency with Healthcare Professionals (HCPs), Healthcare Organizations (HCOs) and Healthcare Institutions (HCIs) and pharmaceutical companies for the betterment of the well-being and health of the patients. Cooperation between pharmaceutical companies, regulators, HCPs, HCOs, HCIs and patients, is essential for the sustainable improvement of healthcare.

    As per Industry codes and legislation, specifically the code Medicines for Europe, Dr. Reddy’s fully pledges to disclose the transfers of values they make to HCPs, HCOs and HCIs. This includes, for example, sponsorship for travel and registration fees to attend medical congresses, HCP sponsorship fees for speaker arrangements or for chairing meetings and grants to HCOs and HCPs, and for any activities related to research and development.

    Disclosure for UK

    The links below will take you to our disclosures for UK, and to a note on the methodology used to set out the data in the report.
    Disclosure 2022
    Methodology note 

    Data Privacy

    Dr. Reddy’s shall provide disclosure in line with applicable data privacy requirements and legislation and obtain informed consent by all HCPs. In cases where HCPs do not provide informed consent, Dr. Reddy’s will produce the disclosure on an aggregate basis.

    Transparency

    Publication of data relating to business-to-health professionals:

    Dr. Reddy’s has always believed in the importance of transparency with Healthcare Professionals (HCPs), Healthcare Organizations (HCOs) and Healthcare Institutions (HCIs) and pharmaceutical companies for the betterment of the well-being and health of the patients. Cooperation between pharmaceutical companies, regulators, HCPs, HCOs, HCIs and patients, is essential for the sustainable improvement of healthcare.

    As per Industry codes and legislation, specifically the code Medicines for Europe, Dr. Reddy’s fully pledges to disclose the transfers of values they make to HCPs, HCOs and HCIs. This includes, for example, sponsorship for travel and registration fees to attend medical congresses, HCP sponsorship fees for speaker arrangements or for chairing meetings and grants to HCOs and HCPs, and for any activities related to research and development.

    Disclosure for UK

    The links below will take you to our disclosures for UK, and to a note on the methodology used to set out the data in the report.
    Disclosure 2022
    Methodology note 

    Data Privacy

    Dr. Reddy’s shall provide disclosure in line with applicable data privacy requirements and legislation and obtain informed consent by all HCPs. In cases where HCPs do not provide informed consent, Dr. Reddy’s will produce the disclosure on an aggregate basis.

    News & Media

    For more information about Dr. Reddy’s in the news, visit the company news page:

    News